Over the past 20 years, regulations have gradually been put in place to require the reporting of clinical drug trials and their findings. Comprehensive reporting and publication of interventional drug research is essential for two main reasons:

• Informing medical decision-making better by quantifying the biases of publishing only positive studies and discrepancies between planned and published protocols, and
• Avoiding unnecessary patient participation in clinical trials that have already been conducted but not publicly reported or published*

Today, reporting of non-interventional studies is encouraged but not mandatory.

*Nearly half of the trials in the field of cancer remain unpublished 3 years after the end of enrollment.

The completion of this action should make it possible to obtain an exhaustive French directory of health studies that include individual data collection.
This directory is intended to provide metadata on the following items:

• Inclusion criteria
• Study size
• Basic dictionary, developer
• Information on data access

This action is implemented by the IReSP. News on the health studies portal can be found here.